A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Autor: Kaan Kavakli, Mamta Manglani, Ezio Zanon, Christoph Male, Tarek Owaidah, Johnny Mahlangu, Ramabadran Varadarajan, Veronica Soto Arellano, Flora Peyvandi, Alessandra Nunes Loureiro Prezotti, Monica Martinez, Frits R. Rosendaal, Cecil Ross, Suresh Hanagavadi, Suvankar Majumdar, Bulent Zulfikar, Anupam Sachdeva, Brian M. Wicklund, Amal El-Beshlawy, Marilyn J. Manco-Johnson, M. Cerqueira, Dinesh M Nayak, Pier Mannuccio Mannucci, Santiago Bonanad Boix, Nadia P. Ewing, Klaus Schmitt, Angeles Palomo Bravo, Nathan L Kobrinsky, Maria Elisa Mancuso, Shashikant Apte, Mathew Thomas, Isabella Garagiola, Rogelio Paredes Aguilera, Guy Young, Maria Gabriella Mazzucconi, Esperanza Marzouka, Rosario Perez Garrido, Tulika Seth, Bülent Antmen, Mohsen Saleh Elalfy, Peyman Eshghi, E. Santagostino, Mindy L. Simpson, Vijay Ramanan, Daniela Neme, Mehran Karimi, Adriana C Sandoval Gonzalez

Publikováno v: New England Journal of Medicine, 374(21), 2054-2064
NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

WOS: 000376443500008
PubMed ID: 27223147
BACKGROUND The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0706f075d71f088bb7ee2416552359
http://hdl.handle.net/1887/113139

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.

Autor: Chowdary P; Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK., Holmström M; Coagulation Unit, Department of Hematology, Department of Medicine, Karolinska Institute Solna Karolinska University Hospital Stockholm Sweden.; Department of Health, Medicine and Caring Sciences Linköping University Linköping Sweden., Mahlangu JN; Hemophilia Comprehensive Care Centre, Department of Molecular Medicine and Haematology, Faculty of Health Sciences University of the Witwatersrand and National Health Laboratory Service Johannesburg South Africa., Ozelo MC; Hemocentro UNICAMP University of Campinas São Paulo Brazil., Pabinger I; Clinical Division of Hematology and Hemostaseology, Department of Medicine I Medical University of Vienna Vienna Austria., Pasi KJ; Royal London Hospital Haemophilia Centre Barts and The London School of Medicine and Dentistry London UK., Ragni MV; Division of Hematology/Oncology, and Hemophilia Center of Western PA, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA., Shapiro A; Indiana Hemophilia and Thrombosis Center Indianapolis Indiana USA., Barnowski C; Sanofi Waltham Massachusetts USA., Lethagen S; Swedish Orphan Biovitrum AB Stockholm Sweden.; Copenhagen University Copenhagen Denmark.

Publikováno v: Research and practice in thrombosis and haemostasis [Res Pract Thromb Haemost] 2022 Jul 26; Vol. 6 (5), pp. e12760. Date of Electronic Publication: 2022 Jul 26 (Print Publication: 2022).

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH.

Autor: van Galen KPM; Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., d'Oiron R; Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles, APHP Paris Saclay - Hôpital Bicêtre and Inserm U 1176, Le Kremlin Bicêtre, France., James P; Department of Medicine, Queen's University, Kingston, Ontario, Canada., Abdul-Kadir R; Department of Obstetrics and Gynaecology and Katharine Dormandy Haemophilia and Thrombosis Unit, The Royal Free Foundation Hospital and Institute for Women's Health, University College London, London, UK., Kouides PA; University of Rochester, Rochester, New York, USA.; The Mary M. Gooley Hemophilia Center, Rochester, New York, USA., Kulkarni R; Michigan State University, East Lansing, Michigan, USA., Mahlangu JN; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Othman M; School of Medicine, Queen's University, and School of Baccalaureate Nursing, St. Lawrence College, Kingston, Ontario, Canada., Peyvandi F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy., Rotellini D; National Hemophilia Foundation, Gibsonia, Pennsylvania, USA., Winikoff R; Department of Pediatric, Service of Hematology, Sainte-Justine Hospital, Montreal, Quebec, Canada., Sidonio RF; Aflac Cancer and Blood Disorders, Emory University, Decatur, Georgia, USA.

Publikováno v: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2021 Aug; Vol. 19 (8), pp. 1883-1887.

Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.

Autor: Oldenburg J; Department of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany., Tran H; The Alfred Hospital, Melbourne, Vic., Australia., Peyvandi F; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Fondazione Ca, Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy., Núñez R; Hospital Universitario Virgen Del Rocio, Seville, Spain., Trask P; Genentech, Inc., South San Francisco, CA, USA., Chebon S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Mahlangu JN; Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa., Lehle M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Jiménez-Yuste V; La Paz University Hospital, Autónoma University, Madrid, Spain., von Mackensen S; Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 May; Vol. 27 (3), pp. 398-407. Date of Electronic Publication: 2021 Feb 12.

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.

Autor: Mancuso ME; Centre for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy. Electronic address: mariaelisa_mancuso@libero.it., Mahlangu JN; Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa., Pipe SW; Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA.

Publikováno v: Lancet (London, England) [Lancet] 2021 Feb 13; Vol. 397 (10274), pp. 630-640. Date of Electronic Publication: 2021 Jan 15.